Hypofractionated Stereotactic Radiotherapy to Surgical Cavity After Resection for Brain Metastasis

Article

Hypofractionated stereotactic radiotherapy (SRT) appears to be safe and effective in preventing recurrence at resection cavities following surgical resection of brain metastasis and may spare many patients from whole brain radiotherapy (WBRT) and its adverse effects.

Hypofractionated stereotactic radiotherapy (SRT) appears to be safe and effective in preventing recurrence at resection cavities following surgical resection of brain metastasis and may spare many patients from whole brain radiotherapy (WBRT) and its adverse effects, according to Hsiang-Hsuan M. Yu, MD, of the Moffitt Cancer Center in Tampa, Florida (AACR abstract 737).

MRI of brain. (Top left) Initial MRI shows a tumor in the right and left frontal lobe as well as the right thalamus. (Top right) MRI after surgery, radiation, and chemotherapy. The tumor has completely disappeared except for slight enhancement adjacent to the surgical margin. (Bottom left) Increase in size of the thalamic tumor two months after stereotactic radiotherapy. (Bottom right) After 6 cycles of TMZ therapy, the thalamic lesion enlarged, and the patient developed dysarthria and hemiparesis. Source: Fujimaki T, Ishii H, Matsuno A, Arai H, Nakagomi T. Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma.World J Surg Oncol. 2007 Aug 4;5:89.

To investigate the efficacy of postoperative hypofractionated SRT after resection of brain metastasis, investigators retrospectively analyzed 52 consecutive patients with brain metastasis from solid tumors who underwent surgical resection followed by SRT to the resection cavity for at least 1 metastasis.

A total of 25 to 30 Gy in 5 daily fractions over a 1-week period was prescribed to the resection cavity with a margin of 2 mm expansion (median dose 28.5 Gy) between 2 to 4 weeks postoperatively.

Synchronous oligometastasis, if present, was treated with radiosurgery. No patients received upfront WBRT. All patients were followed up for at least 6 months. The radiographic end point was local tumor control at resection cavity.

Preliminary analyses showed a local control rate of 86% at 12 months at the resection site; none of the patients developed radiation-induced injury at the resection site.

Although WBRT decreases the risk of recurrence at the resection site, it is also associated with neurocognitive complications. Postoperative radiosurgery is a new technique aimed at decreasing recurrence and sparing patients from WBRT, but a single high-dose fraction may increase radiation-induced necrosis.

“Hypofractionated SRT delivers a higher radiobiological dose which may potentially provide higher local tumor control, and fractionation may lower risk of radiation-induced injury,” explained Dr. Yu.

Recent Videos
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.